CN100346777C - 包括罗氟斯特和福莫特罗的新的协同组合 - Google Patents

包括罗氟斯特和福莫特罗的新的协同组合 Download PDF

Info

Publication number
CN100346777C
CN100346777C CNB2003801037450A CN200380103745A CN100346777C CN 100346777 C CN100346777 C CN 100346777C CN B2003801037450 A CNB2003801037450 A CN B2003801037450A CN 200380103745 A CN200380103745 A CN 200380103745A CN 100346777 C CN100346777 C CN 100346777C
Authority
CN
China
Prior art keywords
formoterol
roflumilast
medicine
pharmacy
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801037450A
Other languages
English (en)
Chinese (zh)
Other versions
CN1713903A (zh
Inventor
罗尔夫·博伊姆
丹尼拉·邦休
诺伯特·科拉萨
德根哈德·马克斯
克里斯蒂安·韦马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Publication of CN1713903A publication Critical patent/CN1713903A/zh
Application granted granted Critical
Publication of CN100346777C publication Critical patent/CN100346777C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CNB2003801037450A 2002-11-27 2003-11-26 包括罗氟斯特和福莫特罗的新的协同组合 Expired - Fee Related CN100346777C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27
EP02026505.4 2002-11-27

Publications (2)

Publication Number Publication Date
CN1713903A CN1713903A (zh) 2005-12-28
CN100346777C true CN100346777C (zh) 2007-11-07

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801037450A Expired - Fee Related CN100346777C (zh) 2002-11-27 2003-11-26 包括罗氟斯特和福莫特罗的新的协同组合

Country Status (31)

Country Link
US (1) US20060142308A1 (enExample)
EP (1) EP1567139B1 (enExample)
JP (1) JP2006508994A (enExample)
KR (1) KR101071798B1 (enExample)
CN (1) CN100346777C (enExample)
AT (1) ATE399543T1 (enExample)
AU (1) AU2003292120B2 (enExample)
BR (1) BR0316451A (enExample)
CA (1) CA2506962C (enExample)
CO (1) CO5690570A2 (enExample)
CY (1) CY1110369T1 (enExample)
DE (1) DE60321953D1 (enExample)
DK (1) DK1567139T3 (enExample)
EA (1) EA009935B1 (enExample)
ES (1) ES2309357T3 (enExample)
HR (1) HRP20050579B1 (enExample)
IL (1) IL168308A (enExample)
IS (1) IS2575B (enExample)
MA (1) MA27539A1 (enExample)
ME (1) ME00489B (enExample)
MX (1) MXPA05005437A (enExample)
NO (1) NO334247B1 (enExample)
NZ (1) NZ540659A (enExample)
PL (1) PL216752B1 (enExample)
PT (1) PT1567139E (enExample)
RS (1) RS51081B (enExample)
SI (1) SI1567139T1 (enExample)
TN (1) TNSN05131A1 (enExample)
UA (1) UA83018C2 (enExample)
WO (1) WO2004047829A1 (enExample)
ZA (1) ZA200503308B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104994854A (zh) * 2013-01-28 2015-10-21 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
PT2359826E (pt) * 2006-07-05 2014-01-20 Takeda Gmbh Combinação de um inibidor da hmg-coa redutase rosuvastatina e um inibidor da fosfodiesterase 4, tais como roflumilaste, óxido de n-roflumilaste, para o tratamento de doenças pulmonares inflamatórias
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370081A (zh) * 1999-08-21 2002-09-18 比克·古尔顿·劳姆贝尔格化学公司 增效组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
TR199901772T2 (enExample) * 1997-02-17 1999-09-21 Byk Gulden Lomberg Chemische Fabrik Gmbh
PT975347E (pt) * 1997-02-28 2008-05-23 Nycomed Gmbh Combinação sinérgica de inibidores da pde e agonistas da adenilato ciclase ou agonistas da guanil ciclise
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
CA2341488A1 (en) * 1998-08-26 2000-03-09 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE381537T1 (de) * 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
AR033290A1 (es) * 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1370081A (zh) * 1999-08-21 2002-09-18 比克·古尔顿·劳姆贝尔格化学公司 增效组合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104994854A (zh) * 2013-01-28 2015-10-21 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
CN110403922A (zh) * 2013-01-28 2019-11-05 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
CN110464724A (zh) * 2013-01-28 2019-11-19 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法

Also Published As

Publication number Publication date
ES2309357T3 (es) 2008-12-16
MXPA05005437A (es) 2005-08-03
HRP20050579B1 (hr) 2014-01-31
JP2006508994A (ja) 2006-03-16
CA2506962C (en) 2012-01-03
IS2575B (is) 2010-02-15
NO334247B1 (no) 2014-01-20
KR20050085104A (ko) 2005-08-29
KR101071798B1 (ko) 2011-10-11
CO5690570A2 (es) 2006-10-31
DK1567139T3 (da) 2008-11-03
AU2003292120B2 (en) 2010-01-21
PL216752B1 (pl) 2014-05-30
ATE399543T1 (de) 2008-07-15
CA2506962A1 (en) 2004-06-10
PT1567139E (pt) 2008-10-01
DE60321953D1 (de) 2008-08-14
EA200500774A1 (ru) 2005-12-29
US20060142308A1 (en) 2006-06-29
IS7898A (is) 2005-06-20
NO20052999L (no) 2005-06-17
EA009935B1 (ru) 2008-04-28
UA83018C2 (uk) 2008-06-10
RS20050382A (sr) 2007-08-03
PL377732A1 (pl) 2006-02-06
WO2004047829A8 (en) 2005-06-30
SI1567139T1 (sl) 2008-12-31
CY1110369T1 (el) 2015-04-29
AU2003292120A1 (en) 2004-06-18
ME00489B (me) 2011-10-10
CN1713903A (zh) 2005-12-28
BR0316451A (pt) 2005-10-11
MA27539A1 (fr) 2005-09-01
ZA200503308B (en) 2006-11-29
HK1081861A1 (en) 2006-05-26
TNSN05131A1 (en) 2007-05-14
RS51081B (sr) 2010-10-31
HRP20050579A2 (hr) 2006-04-30
WO2004047829A1 (en) 2004-06-10
IL168308A (en) 2010-12-30
NZ540659A (en) 2007-05-31
EP1567139B1 (en) 2008-07-02
EP1567139A1 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
CN1370081A (zh) 增效组合物
CN1314811A (zh) 治疗肺病的方法
EP1718336A2 (en) Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
AU2005316687B2 (en) Compositions and methods for pulmonary conditions
CN1235545A (zh) 含有氯雷他定和减充血剂的用于治疗哮喘的组合物
CN1713903A (zh) 包括罗氟斯特和福莫特罗的新的协同组合
EP1567140B1 (en) Synergistic combination comprising roflumilast and (r,r)-formoterol
HK1081861B (en) New synergistic combination comprising roflumilast and formoterol
HK1081862B (en) Synergistic combination comprising roflumilast and (r,r)-formoterol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: NICOMEDES LIMITED LIABILITY COMPANY

Free format text: FORMER OWNER: OTANA MEDICINE AG

Effective date: 20080418

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20080418

Address after: Konstanz

Patentee after: NYCOMED GmbH

Address before: Konstanz

Patentee before: ALTANA PHARMA AG

C56 Change in the name or address of the patentee

Owner name: NYCOMED INC.

Free format text: FORMER NAME: NYCOMED GMBH

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: Nycomed GmbH

Address before: Konstanz

Patentee before: Nycomed GmbH

C56 Change in the name or address of the patentee

Owner name: TAKEDA GMBH

Free format text: FORMER NAME: NYCOMED INC.

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: TAKEDA GmbH

Address before: Konstanz

Patentee before: Nycomed GmbH

ASS Succession or assignment of patent right

Owner name: NYCOMED ASSET MANAGEMENT GMBH

Free format text: FORMER OWNER: TAKEDA GMBH

Effective date: 20150619

Owner name: NYCOMED GERMANY HOLDING GMBH

Free format text: FORMER OWNER: NYCOMED ASSET MANAGEMENT GMBH

Effective date: 20150619

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: TAKEDA GMBH

Free format text: FORMER NAME: NYCOMED GERMANY HOLDING GMBH

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: TAKEDA GmbH

Address before: Konstanz

Patentee before: Nycomed Germany holding LLC

TR01 Transfer of patent right

Effective date of registration: 20150619

Address after: Konstanz

Patentee after: Nycomed Germany holding LLC

Address before: Konstanz

Patentee before: Nycomed asset management LLC

Effective date of registration: 20150619

Address after: Konstanz

Patentee after: Nycomed asset management LLC

Address before: Konstanz

Patentee before: TAKEDA GmbH

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20170105

Address after: Swedish Suo de Jie

Patentee after: ASTRAZENECA AB

Address before: Konstanz

Patentee before: TAKEDA GmbH

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071107

Termination date: 20171126

CF01 Termination of patent right due to non-payment of annual fee